Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Righttothetopon Jul 30, 2021 10:27am
175 Views
Post# 33631749

RE:RE:technical420 article

RE:RE:technical420 articleT420 puts out a good briefing note....and they do and have done a decent job at distilling LABS, even if it's a paid advert.

Doubt anything meaningful comes this Q as well.....but it really would be the next couple after that which should really start to show Stada impact specifically. 

But it's awful quiet on the CEO front, so it's either no one wants to job (or at least at the price it's being offered at) or the candidate pool is weak....neither is all that good.  We can't handle a middle level BD guy taking over simply because he has 20 yrs 'in pharma'......

Starkicker wrote: I guess we'll see what kind of undervalued growth story they are in the next month or so. I've got Q2 revenue estimated at $9.1 million, which won't move the yardsticks much.


<< Previous
Bullboard Posts
Next >>